Login / Signup
Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).
David S Goldfarb
John C Lieske
Jaap Groothoff
Gesa Schalk
Kerry Russell
Shuli Yu
Blaz Vrhnjak
Published in:
Urolithiasis (2023)
Keyphrases
</>